News

How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?
AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...
Eli Lilly's 3-step strategy to dominate the $95 billion obesity market
Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...
Investing Snacks2d
Non-Obesity Drugs Drive Lilly’s Steady Sales Growth
Eli Lilly’s blockbuster GLP-1 drugs dominate headlines, but its broader portfolio deserves a standing ovation for driving ...
Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?
NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.
Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth
LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.
STAT8d
Pharmalittle: We’re reading about Novo’s Wegovy launch gaffes, a former Pfizer exec’s subpoena, and more
Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...
Novo Nordisk, Eli Lilly face first major obesity drug rival in China as Innovent gains approval for mazdutide
Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...
Zacks Investment Research on MSN12d
NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?
Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...
Nasdaq14d
3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow
Meanwhile, Lilly is notching win after win. Eli Lilly's position in the weight management market makes its stock attractive, considering how fast this area is projected to grow in the coming years.